Cite

    Miyama, Y. et al. (2022). Lower neutrophil‐to‐lymphocyte ratio and positive programmed cell death ligand‐1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma. Cancer medicine. pp. 4236-4245. [Online].